Impax launches generic Renvela

Impax Laboratories' (IPXL) +1.8%) Global Pharamaeuticals division launches its generic version of Genzyme's (SNY +0.2%) Renvela (sevelamer carbonate).

The company will sell a specific allotment of bottles granted under a license from Genzyme. Impax's aNDA for the product is currently under regulatory review.

The U.S. Renvela market is ~$900M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs